Sponsor: Memorial Sloan-Kettering Cancer Center
Sponsor Study ID: c16-174
Study Title: DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium 223 for Metastatic Castration Resistant Prostate Cancer (mCRPC)
CTO #: 103022
NCT Number: NCT03574571
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Prostate
Study Objectives: This is an open-labeled, randomized, phase III study of docetaxel versus docetaxel in combination with radium-223 in subjects with mCRPC. The primary objective is to compare overall survival for subjects treated with docetaxel versus subjects treated with docetaxel plus radium-223.